IPO
IPO filing, visualized

Rezera Inc.

Oral NLRP3 inhibitors for inflammation

RZRA · NasdaqS-1/A · Nov 9, 2026Price range set

Pricing expected any day (our estimate) · latest SEC filing Nov 9, 2026.

Pinch-zoom for details.

The offering

Price range
$11–$13
per share
Shares offered
16.7M
sold by the company
Raise at $12 midpoint
$200M
16,666,667 × $12, before fees

Use of proceeds, per the filing: With existing cash, to take ruvonoflast through Phase 3 topline data in PAD, expected in 2028.

What the company does

Rezera is a clinical-stage biotech developing oral drugs that block NLRP3, a driver of inflammation. Its lead drug, ruvonoflast, is headed into a Phase 3 trial in peripheral artery disease (PAD).

Operating result

Fiscal year

1st half

Net result

Fiscal year

1st half

Cash before and after the IPO

Cash and equivalents on the latest balance sheet, actual and as adjusted for the offering, as shown in the filing.

Things to weigh

  • Loss-making: net loss of $25.5M in H1 2026.
  • No approved products; the summary statement of operations shows no revenue.

The numbers

$FY2024FY2025YoYH1 2025H1 2026Change
Operating result(23.4M)(41.0M)−75.2%(13.9M)(24.6M)−76.3%
Net result(25.2M)(42.2M)−67.3%(13.7M)(25.5M)−86.1%
$FY2024FY2025YoY
Operating result(23.4M)(41.0M)−75.2%
Net result(25.2M)(42.2M)−67.3%
$H1 2025H1 2026Change
Operating result(13.9M)(24.6M)−76.3%
Net result(13.7M)(25.5M)−86.1%

Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.

Risks

  1. No revenue from drug sales yet, and a short history.
  2. Has lost money and expects losses to continue.
  3. Will need to raise a lot more money.
  4. Targets NLRP3, a new drug target, so development is hard to predict.
  5. Depends heavily on its lead drug, ruvonoflast.

In plain English, from the filing's risk factors.

Strategy

  1. Get ruvonoflast approved for peripheral artery disease (PAD).
  2. Sell ruvonoflast in the U.S. itself.
  3. Test ruvonoflast in other heart and artery diseases.
  4. Move its second drug into a Phase 2 trial.
  5. Add more anti-inflammation drugs, in-house or by licensing.

In plain English, from the filing's strategy section.

Source: Rezera Inc.'s Form S-1/A, filed with the SEC on Nov 9, 2026 (preliminary prospectus). Figures are as filed; changes are worked out from them. Not investment advice.

10KDecoder10KDecoder.com

10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.